MX2021006127A - Terapias de combinacion para sindromes mielodisplasicos (mds) de alto y muy alto riesgo. - Google Patents

Terapias de combinacion para sindromes mielodisplasicos (mds) de alto y muy alto riesgo.

Info

Publication number
MX2021006127A
MX2021006127A MX2021006127A MX2021006127A MX2021006127A MX 2021006127 A MX2021006127 A MX 2021006127A MX 2021006127 A MX2021006127 A MX 2021006127A MX 2021006127 A MX2021006127 A MX 2021006127A MX 2021006127 A MX2021006127 A MX 2021006127A
Authority
MX
Mexico
Prior art keywords
combination therapies
risk mds
high risk
mds
pracinostat
Prior art date
Application number
MX2021006127A
Other languages
English (en)
Inventor
Richard Ghalie
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of MX2021006127A publication Critical patent/MX2021006127A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se proporcionan métodos para tratar MDS de alto y muy alto riesgo que comprenden administrar pracinostato y un agente hipometilador de ADN.
MX2021006127A 2018-11-30 2019-11-26 Terapias de combinacion para sindromes mielodisplasicos (mds) de alto y muy alto riesgo. MX2021006127A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773490P 2018-11-30 2018-11-30
PCT/US2019/063360 WO2020112848A1 (en) 2018-11-30 2019-11-26 Combination therapies for high and very high risk mds

Publications (1)

Publication Number Publication Date
MX2021006127A true MX2021006127A (es) 2021-06-23

Family

ID=70854408

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006127A MX2021006127A (es) 2018-11-30 2019-11-26 Terapias de combinacion para sindromes mielodisplasicos (mds) de alto y muy alto riesgo.

Country Status (14)

Country Link
US (1) US20220016082A1 (es)
EP (1) EP3886865A4 (es)
JP (1) JP2022511746A (es)
KR (1) KR20210097157A (es)
CN (1) CN113412115A (es)
AU (1) AU2019389004A1 (es)
BR (1) BR112021010101A2 (es)
CA (1) CA3121188A1 (es)
EA (1) EA202191503A1 (es)
IL (1) IL283464A (es)
MA (1) MA54322A (es)
MX (1) MX2021006127A (es)
SG (1) SG11202105506UA (es)
WO (1) WO2020112848A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
ES2774296T3 (es) * 2012-10-30 2020-07-20 Mei Pharma Inc Terapias de combinación para tratar cánceres quimiorresistentes
US10052346B2 (en) * 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids

Also Published As

Publication number Publication date
MA54322A (fr) 2021-10-06
EP3886865A4 (en) 2022-11-23
IL283464A (en) 2021-07-29
US20220016082A1 (en) 2022-01-20
EP3886865A1 (en) 2021-10-06
CA3121188A1 (en) 2020-06-04
WO2020112848A1 (en) 2020-06-04
JP2022511746A (ja) 2022-02-01
KR20210097157A (ko) 2021-08-06
EA202191503A1 (ru) 2021-11-15
BR112021010101A2 (pt) 2021-08-24
CN113412115A (zh) 2021-09-17
AU2019389004A1 (en) 2021-07-15
SG11202105506UA (en) 2021-06-29

Similar Documents

Publication Publication Date Title
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
PH12017501857A1 (en) Pd-l1 antagonist combination treatments
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
PH12017550063A1 (en) Combination therapies for treating cancers
WO2017177179A9 (en) Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
PH12017502103A1 (en) Methods and kits for treating depression
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
IL270511A (en) Combined treatments using niraparib and pembrolizumab for the treatment of cancer
BR112018007656A2 (pt) terapia de combinação para tratamento de doenças malignas
MX2017002364A (es) Terapia de combinacion para tratamiento de cancer.
BR112018008882A2 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
MX2018015172A (es) Metodos para tratar cancer pancreatico.
MX2020001727A (es) Terapia de combinacion.
MX2019002108A (es) Terapia de combinacion con inhibidores de glutaminasa.
MX2017015311A (es) Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.
MX2018001515A (es) Combinaciones de un anticuerpo ox40 y un modulador tlr4 y usos de las mismas.
PH12017500275A1 (en) Methods of treating depression using nmda modulators
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
NZ734750A (en) Cancer therapy with a parvovirus combined with bevacizumab
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
MX2019003314A (es) Metodos de tratamiento de la elevacion de dominio 3 de inmunoglobulina de celula t y mucina (tim-3).